Abstract: A composite dura substitute implant for implantation at a dura defect site having a porous layer that provides an osteoconductive scaffold for bony ingrowth, a porous layer that provides a scaffold for regeneration of collagen at a dura surface, and an intervening layer for preventing cerebrospinal leakage is disclosed. The composite dura substitute implant facilitates regeneration of dura mater and promotes osteointegration with bony tissue. Methods of manufacturing such an implant and methods of treatment using such composite dura substitute implants are further disclosed.

Abstract: The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers. The reprogramming is accomplished by contacting the adult cells with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. Without being limited by theory, platelet-like cells and their released mitochondria display immune tolerance-associated markers that may modulate the function and differentiation of immune cells.

Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

Abstract: The invention provides systems, modules, bioreactor and methods for the automated culture, proliferation, differentiation, production and maintenance of tissue engineered products. In one aspect is an automated tissue engineering system comprising a housing, at least one bioreactor supported by the housing, the bioreactor facilitating physiological cellular functions and/or the generation of one or more tissue constructs from cell and/or tissue sources. A fluid containment system is supported by the housing and is in fluid communication with the bioreactor. One or more sensors are associated with one or more of the housing, bioreactor or fluid containment system for monitoring parameters related to the physiological cellular functions and/or generation of tissue constructs; and a microprocessor linked to one or more of the sensors. The systems, methods and products of the invention find use in various clinical and laboratory settings.

Abstract: Embodiments herein are directed to moisturizing compositions comprising interpenetrating polymer networks, methods of making moisturizing compositions and methods of using moisturizing compositions.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Abstract: A biomaterial for the treatment of spinal cord or of peripheral nerve injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and culturing and expanding the absorbed cells in the presence of growth or neurotrophic factors selected from ?FGF (basic fibroblast growth factor), CNTF (ciliary neurotrophic factor), BDNF (brain derived neurotrophic factor) and GDNF (glial derived neurotrophic factor) or mixtures thereof.

Abstract: The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.

Abstract: Particles and related methods are disclosed.

Abstract: A water-absorbing polymer obtained from polymerization of (A) and (B) in aqueous medium wherein (A) is a phosphate-containing (meth)acrylic monomer and/or a salt thereof, and (B) is a monomer having one (meth)acrylic group within the molecule and/or a salt thereof that is different from component (A); and reacting the reaction product of (A) and (B) with (C) an organopolysiloxane having a (meth)acrylic group at both ends.

Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

Abstract: Embodiments of the present disclosure provide for electroactive supramolecular polymeric assemblies, methods of making electroactive supramolecular polymeric assemblies, methods of using electroactive supramolecular polymeric assemblies, and the like.

Abstract: The present disclosure provides tissue products produced from extracellular tissue matrices. The tissue products can include acellular extracellular matrices including combinations of different tissue types. The combination can harness various properties of the different tissues to provide improved composite structures with desired mechanical and/or biologic properties.

Abstract: Disclosed is a medical device having a first implant portion having a proximal end, a second implant portion connected to the first implant portion, the second implant portion having a distal end, and a driver assembly removably connected to the distal end, the driver assembly comprising a drill connected to the distal end at a connection.

Abstract: Biocompatible implantable sensor apparatus and methods of implantation and use. In one embodiment, the sensor apparatus is an oxygen-based glucose sensor having biocompatibility features that mitigate the host tissue response. In one variant, these features include use of a non-enzymatic membrane over each of the individual analyte detectors so as to preclude contact of the surrounding tissue with the underlying enzyme or other matrix, and mitigate vascularization, and insulation of the various electrodes and associated electrolytic processes of the sensor from the surrounding tissue. In one implementation, the sensor region of the implanted apparatus is configured to interlock or imprint the surrounding tissue so as to promote a high degree of glucose molecule diffusion into the individual detectors, and a constant and predictable sensor to blood vessel interface, yet preclude the tissue from bonding to the sensor, especially over extended periods of implant.

Abstract: Described is a group of polymeric calcific heart valves with different levels of calcification that can be used for research and development studies related to transcatheter heart valve technologies. Using a heart flow simulator, the valves' function was studied in aortic position in the presence or absence of an implanted transcatheter aortic valve (valve-in-valve). Through multiple experiments based on echocardiography, it was found that these calcific valves can suitably mimic the function of a native calcified stenotic aortic valve and can be used for valve-in-valve studies. Using this novel polymeric calcified valve provides a desired cost-saving solution for testing the performance of new TAVR systems in vitro and in vivo.

Abstract: The invention herein relates to the field of attaching and securing manmade material onto or into bone in correcting bone defects by implanting stress-bearing bone replacements. In particular, the invention relates to applying a coating of collagen securely onto the implant to ensure the collagen material will not be removed from the implant during installation, such as screwing the anchor into the bone. This addresses the removal of the coatings by the scraping action of the bone on the soft collagen. In the past, it has not been possible to provide adequate adhesive strength to the bone collagen/implant interface or the cohesive force of the collagen itself to prevent the removal of the coating by the abrasive action between bone and known implants.

Abstract: A tubular patch (3) made of PGA fabric, optionally containing within it a mesh tubular support in PGA/PLA, for implantation to replace one or more urethral and/or ureteral removed segments for use in tissue reconstruction of the removed segments for the treatment of diseases such as necrosis, stenosis, tumours, trauma, iatrogenic injuries and the like, or congenital malformations.

Abstract: Methods of treating an adult mammal for an aging-associated condition are provided. Aspects of the methods include enhancing a TIMP activity, e.g., a TIMP2 activity, in the mammal in a manner sufficient to treat the adult mammal for the aging-associated condition. Also provided are compositions for use in practicing methods of the invention. A variety of aging-associated conditions may be treated by practice of the methods, which conditions include cognitive impairments.

Abstract: Compositions and blends of biopolymers and copolymers are described, along with their use to prepare biocompatible scaffolds and surgically implantable devices for use in supporting and facilitating the repair of soft tissue injuries.

Abstract: To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 90% or less is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film. If necessary, a metal oxide layer made of a metal oxide having an isoelectric point of less than 7 is formed on the bioimplant thereby suppressing adhesion of bacteria.

Abstract: A bone repair composition and methods thereof include bone fibers made from cortical bone in which a plurality of bone fibers are made into various implant shapes conducive to introduction into a patient through minimally invasive surgery. The bone fiber compositions may be in the form of a pellet or cylinder. A method includes producing the bone fiber graft efficiently with control of key parameters of cohesiveness, rehydration and swelling of the bone fiber graft. Another method includes introducing the bone fiber graft into the cannula efficiently. A method is also provided to allow introduction of a bone graft into a patient by placing the implant in a tube and expelling it through the action of a plunger.

Abstract: The present invention relates to a peptide for promoting bone formation or inhibiting bone resorption and use thereof. The peptide for regulating bone formation or bone resorption of the present invention has the effect of promoting bone formation by enhancing osteoblast differentiation and concurrently inhibiting bone resorption by restricting osteoclast differentiation and resorptive function. Additionally, due to the low molecular weight, the peptide can be economically produced, and is thus useful for preventing and treating bone diseases.

Abstract: A substrate processing method for forming fully self-aligned vias. The method may be performed in a batch processing system that is capable of simultaneously processing multiple substrates, where the batch processing system includes a process chamber containing processing spaces defined around an axis of rotation in the process chamber. Each of the substrates contain a first surface and a second surface, and the method includes selectively forming SiO2 raised features on the first surface relative to the second surface.

Abstract: A biosensor includes an array of metal nanorods formed on a substrate. An electropolymerized conductor is formed over tops of a portion of the nanorods to form a reservoir between the electropolymerized conductor and the substrate. The electropolymerized conductor includes pores that open and close responsively to electrical signals applied to the nanorods. A dispensing material is loaded in the reservoir to be dispersed in accordance with open pores.

Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Abstract: Provided is a method for manufacturing an electrode material having a pressing step in which an irregularly shaped aggregate containing at least an active material is statically pressed in the presence of an alkali metal source and a solvent.

Abstract: A system and method for automatically calculating an accurate recommended dosage for hormone replacement therapy and automating the life cycle of a patient's treatment over time. The system and method can automatically acquire relevant patient parameters and apply a consistent formulaic approach to help reduce incorrect dosage determinations. A pellet insertion size may be determined and documented based on a calculated dosage, and an insertion side and lot numbers may be tracked and managed. In addition, corresponding revenues may be tracked and profitability may be reported for hormone replacement therapy practices.

Abstract: A process of making compositions comprising benefit agent delivery particles comprises the steps of combining a graft co-polymer and a benefit agent to form a premix composition, and combining the premix composition and water and/or consumer product adjunct material to form the compositions. The resulting compositions comprise benefit agent delivery particles that comprise the graft co-polymer and benefit agent.

Abstract: A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.

Abstract: A bone graft composition includes a biologically-resorbable cement and a plurality of processed bone particles, where each of the bone particles have a shape configured to interconnect with adjacent bone particles. A method for treating a bone defect using the bone graft compositions includes providing the bone graft composition and administering an effective amount of the bone graft composition to a site of a bone defect in a subject. Kits including a biologically-resorbable cement powder and a plurality of processed bone particles are also provided.

Abstract: The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.

Abstract: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, thereby allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.

Abstract: A biocompatible curable composition and a method of detecting a border of a tumor, a tissue of interest, or both including injecting the biocompatible curable composition and contacting the border of a tumor or a tissue, the biocompatible curable composition crosslinks to form a three-dimensional cured nanocomposite, and imaging the three-dimensional (3D) cured nanocomposite, and imaging the 3D cured nanocomposite by at least one of MRI, CT, ultrasound, and X-ray, to detect the border of the tumor or the tissue of interest or track tumor motion during radiotherapy treatment. The biocompatible curable composition comprising an organic polymer having a hydrolysable functional group, a metallic nanoparticle, and a polar or a non-polar solvent. A brachytherapy strand consisting of a biocompatible curable composition and a radio-isotope seed. The biocompatible curable composition is shaped into an elongated cylinder and forms a 3D cured nanocomposite with a radio-isotope seed embedded.

Abstract: The method of making a hydrolyzed collagen gel is a manufacturing method for producing a hydrolyzed collagen gel to be used as a topical wound treatment. A first volume of purified water is initially heated to a temperature ranging from about 71° C. to about 77° C., and a hydrolyzed type I collagen powder is then mixed into the heated purified water to form a first mixture. An additive is mixed into the first mixture to form a second mixture, where the additive may be native collagen, at least one amino acid, least one therapeutic agent, gelatin, whey, hydrolyzed whey, polysulfated glycosaminoglycan, a glucosamine salt, glutamine, glycosaminoclycans, zinc, silver oxide alginates, cellulose, honey, mushroom extract and combinations thereof. A second volume of purified water is then added to the second mixture to form the hydrolyzed collagen gel product. Mixing is performed as a continuous, recirculating, temperature-monitored and temperature-maintained process.

Abstract: A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.

Abstract: A semi-synthetic hybrid material having a pH from 7 to 7.4 includes an inorganic fraction and a cross-linked organic fraction. The method for producing this material, and osteosynthesis devices or implants made of semi-synthetic hybrid material are also described.

Abstract: A medical grade thermoplastic or polymer implant with an osteoconductive coating is provided, specifically for corrections of the distal and proximal interphalangeal toe joints of the foot. The implant can be either straight or angled, and can be either solid or cannulated for insertion. The implant is sized and shaped depending on the specific anatomy and desired correction. End portions of the implant may be coated with an osteoconductive coating that promotes bone growth, but may reduce radiolucency. Thus, a central portion of the implant may remain uncoated to increase radiolucency of the implant at the region where two bones come together.

Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.

Abstract: Adjunct materials for delivery to liver tissue are provided. In general, the adjunct materials can be configured to be delivered to tissue by deployment of staples from a cartridge body of a surgical stapler. The adjunct material is configured to transition from an unexpanded configuration to an expanded configuration after delivery thereof to the liver tissue. The adjunct material can include an effective amount of one or more medicants, such as a hemostatic agent or a tissue healing agent, disposed within and releasable from the adjunct material for delivery to the liver tissue. The adjunct material can expand to apply pressure to liver tissue to facilitate sealing of one or more fractures in the stapled liver tissue. Methods of using a staple cartridge assembly or an end effector to apply such adjunct materials to liver tissue are also provided.

Abstract: The present invention aims to provide a method for producing a porous tissue regeneration substrate that allows a wide choice of solvents and easy adjustment of the bulk density and pore size of the porous substrate. The present invention also aims to provide a method for producing an artificial blood vessel and an artificial blood vessel. The present invention relates a porous, tubular artificial blood vessel containing a bioabsorbable material, the artificial blood vessel including: a skin layer having a relatively small pore size as an innermost layer; and a porous layer positioned around the skin layer and having a relatively large pore size.

Abstract: An implant that facilitates the fusion of a first bone part with a second bone part includes an implant body that extends between the first bone part and the second bone part. The implant body includes a first portion that fits within a first receiving aperture in the first bone part, and the implant body includes a second portion that fits within a second receiving aperture in the second bone part. At least one of the first portion and the second portion can be made of bone. Additionally, at least the second portion is formed to have a non-circular cross-sectional shape to inhibit relative motion between the bone parts and the implant body.

Abstract: The present disclosure provides a hydrogel composition including: a hydrogel having a structure represented by Formula (I) or Formula (II) shown as follows: A-B-BOX-B-A, Formula (I); B-A-B-(BOX-BAB)n-BOX-B-A-B, Formula (II), wherein, A is a hydrophilic polyethylene glycol polymer, B is a hydrophobic polyester polymer, BOX is a bifunctional group monomer of 2,2?-Bis(2-oxazoline) for coupling di-block of A-B or tri-block of B-A-B, and n is an integer greater than or equal to 0; and an anti-adhesion additive, wherein the anti-adhesion additive comprises a carbohydrate, a nitrogen-containing cyclic compound, a polymer or a combination thereof.

Abstract: The disclosure describes collagen constructs comprising antimicrobial agents and related methods.

Abstract: The present invention relates to a method for purifying a protein belonging to the transforming growth factor-? (TGF-?) superfamily, said method comprising subjecting a cell culture medium containing the protein to a Hydrophobic Charge 5 Interaction Chromatography (HCIC).

Abstract: Method and set of surgical instruments for fitting a shoulder prosthesis, and the shoulder prosthesis. The proposed method seeks to interpose a bone graft between the previously prepared glenoid surface (G) of a scapula (S) of a patient's shoulder and the face of a glenoid prosthetic component opposite the articular surface. The set of instruments permit the bone graft to be taken from the upper epiphysis of the humerus (H), either in situ or ex vivo.

Abstract: Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small, amounts of a polysorbate, and a carrier.

Abstract: A device for sustained delivery of a poorly water soluble drug is described. A drug reservoir within the device, when in operation, contains an aqueous suspension of the drug mixed with a suspension of an excipient that, in one embodiment, generates acidic groups for a sustained period of time to maintain a desired pH in the aqueous suspension that in turn provides a constant concentration of a soluble form of the drug.

Abstract: This invention relates a controlled release delivery composition for an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination, using a chitosan-glycerophosphate (CGP) hydrogel and an agent or a bio-materials. Additionally, provided methods of treating an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination.

Abstract: The present invention relates to an extract of Cynara spp. and also to compositions and kits that comprise said extract for the prevention and/or the treatment of a pathological condition characterized by a constitutive activation of the STAT3 transcription factor.